Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
Status:
Terminated
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to test whether a new drug named visilizumab would decrease the
severity of graft-versus-host disease in patients treated with a mismatched donor.
Investigators planned to use visilizumab in combination with tacrolimus and methotrexate as
the "study treatment".
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborators:
National Cancer Institute (NCI) National Institutes of Health (NIH)